Halozyme Therapeutics, Inc. HALO unveils its next round of earnings this Tuesday, Nov. 6. Get prepared with Benzinga's ultimate preview for Halozyme Therapeutics' Q3 earnings.
Earnings and Revenue
Analysts covering Halozyme Therapeutics have modeled for quarterly EPS loss of 23 cents on revenue of $30.42 million.
In the same quarter last year, Halozyme Therapeutics announced EPS of 2 cents on revenue of $63.73 million. Sales would be down 52.27 percent on a year-over-year basis. Halozyme Therapeutics' reported EPS has stacked up against analyst estimates in the past like this:
| Quarter | Q2 2018 | Q1 2018 | Q4 2017 | Q3 2017 |
| EPS Estimate | -0.22 | -0.22 | 0.06 | |
| EPS Actual | -0.16 | -0.19 | 0.85 | 0.02 |
Stock Performance
Over the last 52-week period, shares are down 5.32 percent. Given that these returns are generally negative, long-term shareholders are likely unhappy going into this earnings release.
Analyst estimates are adjusted lower for EPS and revenues over the past 90 days. The popular rating by analysts on Halozyme Therapeutics stock is a Neutral. The strength of this rating has maintained conviction over the past 90 days.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
